Status: Recruiting
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).
Participants needed: 16
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Misty ShieldsUpdated: Jun 18, 2026Locations: 1
Eligibility criteria
≥ 18 years old at the time of informed consent. [+8]
Patients who have tumors harboring EGFR exon 20 insertion alterations, EGFR C797... [+9]